Navigation Links
Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
Date:5/13/2013

or 510.856.5598.

 ANTHERA PHARMACEUTICALS, INC.(A Development Stage Company)CONDENSED STATEMENTS OF OPERATIONS (in thousands, except share and per share data)(unaudited)Three Months Ended March 31,20132012Operating expenses:Research and development

$

4,929

(1)$

17,738General and administrative1,972

(2)2,322Total operating expenses6,90120,060Loss from operations(6,901)(20,060)Other income (expenses):Other income (expense) - net25(10)Interest expense(704)(843)Total other (expense) - net(679)(853)Net loss attributable to common stockholders

$

(7,580)$

(20,913)Net loss per share attributable to common stockholders:Basic and diluted

 

$

 

(0.06) 

$

 

(0.51)Weighted-average number of shares used to compute net loss per share of common stock—basic and diluted 

124,124,066 

41,000,421(1)

Included in research and development expenses is a one-time charge of stock-based compensation of approximately $799,000 associated with the voluntary surrender of stock options by our employees during the three months ended March 31, 2013.(2)

Included in general and administrative expenses is a one-time charge of stock-based compensation of approximately $661,000 associated with the voluntary surrender of stock options by our employees during the three months ended March 31, 2013. 

 ANTHERA PHARMACEUTICALS, INC.(A Development Stage Company)BALANCE SHEET DATA(in thousands, except share data)(unaudited)March 31, 2013December 31,
2012Cash and cash equivalents

$
50,570$
9,431Short term investments

$
3,824$
5,322Total assets

$
56,452$
26,445Total current liabilities, excluding current portion of notes payable

$
4,706$
9,421Total notes payable

$
8,393$
20,550Deficit accumulated during development
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
2. Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
3. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
5. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
6. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
7. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
8. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
9. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
11. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ("Galmed"), ... and commercialization of a once-daily, oral therapy for ... today announced financial results for the 12 months ... 2014 Highlights: , Hosted a key opinion ... Rohit Loomba, MD, MHSc., who discussed the topic ...
(Date:3/31/2015)... 31, 2015  CVS Health (NYSE: CVS ... clinical affiliations with Rush University Medical Center in ... Medical Center in Tucson, Arizona ... Care. These affiliations will help enhance access to ... these clinical affiliations, CVS Health will provide prescription ...
(Date:3/31/2015)...  Oxis International, Inc. (OXIS) (OXI.PA) a biotechnology company ... today Oxis CEO Tony Cataldo has requested ... on the Euronext exchange. Oxis shares will continue to ... Oxis Chairman and CEO Tony Cataldo ... its strategies launched in 2014 and 2015, we must ...
Breaking Medicine Technology:Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 2Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 3Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 4Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 5Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 6Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 7Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 8CVS Health Announces New Clinical Affiliations with Leading Medical Centers in Arizona and Illinois 2CVS Health Announces New Clinical Affiliations with Leading Medical Centers in Arizona and Illinois 3Oxis International Inc. Announces Request for Euronext Trading Suspension 2
... Calif., June 24, 2011 ... a global leader in the field of radiation oncology, ... Trade Agreement (KORUS FTA), which is currently pending Congressional ... opportunities for U.S. exporters nationwide, the agreement, if ratified, ...
... Pharmaceuticals, Inc. (Nasdaq: AMLN ), Eli Lilly and ... ALKS ) today announced results from an analysis ... diabetes medication BYDUREON™ (exenatide extended-release for injectable suspension) was not ... 2 diabetes. These findings will be presented in a poster ...
Cached Medicine Technology:Accuray Hosts Korean Embassy's Minister for Economic Affairs at Event to Support the U.S.-Korea Free Trade Agreement 2Accuray Hosts Korean Embassy's Minister for Economic Affairs at Event to Support the U.S.-Korea Free Trade Agreement 3Accuray Hosts Korean Embassy's Minister for Economic Affairs at Event to Support the U.S.-Korea Free Trade Agreement 4Analysis Shows BYDUREON™ Was Not Associated with Clinically Relevant QT Prolongation in Patients with Type 2 Diabetes: Results Presented at ADA 2011 2Analysis Shows BYDUREON™ Was Not Associated with Clinically Relevant QT Prolongation in Patients with Type 2 Diabetes: Results Presented at ADA 2011 3Analysis Shows BYDUREON™ Was Not Associated with Clinically Relevant QT Prolongation in Patients with Type 2 Diabetes: Results Presented at ADA 2011 4Analysis Shows BYDUREON™ Was Not Associated with Clinically Relevant QT Prolongation in Patients with Type 2 Diabetes: Results Presented at ADA 2011 5Analysis Shows BYDUREON™ Was Not Associated with Clinically Relevant QT Prolongation in Patients with Type 2 Diabetes: Results Presented at ADA 2011 6Analysis Shows BYDUREON™ Was Not Associated with Clinically Relevant QT Prolongation in Patients with Type 2 Diabetes: Results Presented at ADA 2011 7Analysis Shows BYDUREON™ Was Not Associated with Clinically Relevant QT Prolongation in Patients with Type 2 Diabetes: Results Presented at ADA 2011 8
(Date:3/31/2015)... In conjunction with the Asbestos Awareness ... Mesothelioma Applied Research Foundation (Meso Foundation) announced the ... its existing work in mesothelioma research, education, support, ... Meso Foundation’s mission, we want to eliminate harmful ... asbestos, including mesothelioma,” said the Meso Foundation’s executive ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 In ... (ADS) is offering advice for buying from a ... Dealers Association (NMEDA) is a nonprofit organization that ... in the manufacturing and installation of mobility equipment. ... in the industry that consistently adhere to the ...
(Date:3/31/2015)... Calling all runners, walkers and everyone who ... diseases! The first annual “Lyme Walk & Run” will be ... CT. The event, hosted by Lyme Research Alliance (LRA) ... to support research and education about Lyme and other tick-borne ... and abilities, will feature 5K and 10K runs and one-mile ...
(Date:3/31/2015)... Hollywood, Florida (PRWEB) March 31, 2015 ... that activities like basketball, rock climbing, and cycling are ... called Adaptive Sports at Memorial Rehabilitation Institute aims to ... the Memorial Healthcare System, will host an Adaptive Sports ... p.m.) at Memorial Regional Hospital South in Hollywood. ...
(Date:3/31/2015)... NB (PRWEB) March 31, 2015 Indosoft, developer ... of Asterisk 1.4 support in development of their 5.x line. ... for Asterisk has been deployed around the world for more ... Asterisk 1.4 as a telephony platform, Q-Suite can fully embrace ... providing quality call center software on Asterisk for more than ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Research Organization Announces New Prevention Program 2Health News:Mesothelioma Research Organization Announces New Prevention Program 3Health News:Advanced Driving Systems Celebrates National Disability Month 2Health News:Lyme Research Alliance & Tick-Borne Disease Alliance to Kick-Off 1st “Lyme Walk & Run” Event, April 26 2Health News:Memorial Healthcare System's Adaptive Sports Expo Encourages Physically Challenged To Go Beyond Perceived Limitations 2Health News:Indosoft Announces End of Life for Asterisk 1.4 Support in Q-Suite 5 Call Center Software 2
... person with a disability, MINNEAPOLIS, Nov. 6 ... recipient of the 2008 Judd Jacobson Memorial Award.,Established in ... pursuit or achievement in a business entrepreneurial,endeavor by a ... Kusiak, 48, is a paraplegic as the result of ...
... 2008 A major issue in the development of ... damaged tissues. In a review of the issue published ... regeneration in humans from the body,s own tissues by ... answered before the process can reach clinical status. , ...
... ResMed Inc. (NYSE: RMD ),today announced record ... 2008. Revenue for the quarter was $217.9 million, a ... the current,quarter, income from operations was $36.6 million and ... 16%, respectively, compared to the quarter,ended September 30, 2007. ...
... mass maintenance, study finds , , THURSDAY, Nov. 6 (HealthDay ... bones, which can lead to a decrease in bone ... In previous research, the study authors, from Loyola University ... rats large amounts of alcohol caused significant decreases in ...
... 915, BALTIMORE, Nov. 6 The following ... (Photo: http://www.newscom.com/cgi-bin/prnh/20081105/DC44231LOGO ), WHEN: Tuesday, ... outside the Baltimore Marriott Waterfront Hotel, 700,Aliceanna St., ... Maryland Right to Life, Defend Life and the,Catholic ...
... the Innovative Program Targeting Adolescents, PHILADELPHIA, ... (AHIP) will recognize Independence Blue Cross (IBC) ... adolescents to get the,important, recommended immunizations they ... against dangerous, infectious diseases like,meningitis and HPV, ...
Cached Medicine News:Health News:Wisconsin Farmer Ronald Kusiak Honored With 2008 Jacobson Memorial Award 2Health News:New advancements in the use of adult, embryonic stem cells for tissue regeneration 2Health News:New advancements in the use of adult, embryonic stem cells for tissue regeneration 3Health News:ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008 2Health News:ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008 3Health News:ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008 4Health News:ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008 5Health News:ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008 6Health News:ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008 7Health News:Alcohol Abuse Can Damage Bones 2Health News:Coalition Asks Bishops to Take Politicians to Task 2Health News:Independence Blue Cross Honored for Immunization Program 2Health News:Independence Blue Cross Honored for Immunization Program 3
... A fixed pipette is ideal ... single volume. Fixed volume FInnpipettes ... advantages as other Finnpipette Digital ... Super blow-out (1-40ul), Soft-touch tip ...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
... System is the smallest blood glucose testing system ... you need it in your backpack or ... in your purse or pocket.* Its small size ... And, because it's so convenient it's easier for ...
... Carl Zeiss is expanding the ... of field, excellent color reproduction, high-contrast ... New patented optics provide improved resolution ... SyCoP (Systems Control Panel) combines all ...
Medicine Products: